Grant: Catalyst Grant: Environments, Genes and Chronic Disease
McMaster University
$99,820.00
Early life nutrition, antibiotics, infection and bacterial sensing regulate diabesity
FY 2013-14
Summary
Over one quarter of Canadian children are obese. Over half of Canadian children are prescribed antibiotics. Antibiotic use has recently been implicated in obesity later in life.
Obesity significantly reduces the quality of life in childhood and increases the risk of diabetes and life threatening cardiovascular disease in adulthood. Inflammation and the huge number of bacteria that always live on us have emerged as important factors in causing these diseases during obesity. However, we know very little about the how environmental factors (such as drugs and bacteria) could contribute to obesity. The job of some of our genes is to control the bacteria that live of us and make sure it is not harmful. Bacterial infection still occurs and we often use antibiotics as a treatment. These factors change the bacteria that live in our gut and may contribute to metabolic disease.
We were the first to show that immune sensors for specific parts of bacterial cell wall regulate inflammation and metabolism during obesity. We have now discovered that deletion of a bacterial sensor (NOD2) allows bacteria to escape the gut and invade fat tissue. This contributes to inflammation, obesity, and pre-diabetes. We also have discovered that obesity reduces a type of (Th17-mediated) immunity in the gut. Without this immune response, we cannot properly control the type of bacteria that grows in the gut. These are 2 ways bacteria in our gut play a role in metabolic disease. However, we need to understand how early life bacterial infection and the antibiotics used to treat these infections may interact to promote obesity and diabetes.
This research sets the stage for testing how childhood antibiotic use and eating high fat diet work together to promote obesity-related disease, such as diabetes.
Department
Program
Catalyst Grant: Environments, Genes and Chronic Disease
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
285253
Name
Schertzer Jonathan D
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Catalyst Grant: Environments, Genes and Chronic Disease
Projecttitle
Early life nutrition, antibiotics, infection and bacterial sensing regulate diabesity
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$99,820
Cihrequipment2
$0
Programname2
Catalyst Grant: Environments, Genes and Chronic Disease
Keyworddelim
Adipose Tissue; Antibiotics; Bacteria; Diabesity; Diabetes; Infection; Inflammation; Insulin Resistance; Microbiota; Obesity
Abstract
Over one quarter of Canadian children are obese. Over half of Canadian children are prescribed antibiotics. Antibiotic use has recently been implicated in obesity later in life.
Obesity significantly reduces the quality of life in childhood and increases the risk of diabetes and life threatening cardiovascular disease in adulthood. Inflammation and the huge number of bacteria that always live on us have emerged as important factors in causing these diseases during obesity. However, we know very little about the how environmental factors (such as drugs and bacteria) could contribute to obesity. The job of some of our genes is to control the bacteria that live of us and make sure it is not harmful. Bacterial infection still occurs and we often use antibiotics as a treatment. These factors change the bacteria that live in our gut and may contribute to metabolic disease.
We were the first to show that immune sensors for specific parts of bacterial cell wall regulate inflammation and metabolism during obesity. We have now discovered that deletion of a bacterial sensor (NOD2) allows bacteria to escape the gut and invade fat tissue. This contributes to inflammation, obesity, and pre-diabetes. We also have discovered that obesity reduces a type of (Th17-mediated) immunity in the gut. Without this immune response, we cannot properly control the type of bacteria that grows in the gut. These are 2 ways bacteria in our gut play a role in metabolic disease. However, we need to understand how early life bacterial infection and the antibiotics used to treat these infections may interact to promote obesity and diabetes.
This research sets the stage for testing how childhood antibiotic use and eating high fat diet work together to promote obesity-related disease, such as diabetes.
Competitiondate
201304
Approvedterm2
1 yr 0 mth
Pinamesdelim
Schertzer, Jonathan D; Coombes, Brian K
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Human Dev &Child &Yth~ $49,910~ $0~Inst of Nutr Metabolism &Diab~ $49,910~ $0~